Plain-English translation of NCT06263530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a new blood test called circulating tumor DNA (ctDNA) to see if it can predict how well Hodgkin lymphoma treatment is working and whether the disease might come back. The study will collect blood samples from about 500 newly diagnosed patients at key moments during their cancer treatment — at diagnosis, during chemotherapy, after radiation, and during follow-up care. The goal is to understand whether this blood test can help doctors personalize treatment plans and catch relapses earlier.
Current methods of tracking Hodgkin lymphoma rely on imaging scans, which can be expensive, time-consuming, and sometimes hard to interpret. If a simple blood test can reliably predict treatment response and warn of relapse, it could help doctors make faster, better decisions about whether to continue current treatment or try something different.
You likely qualify if…
You likely don't qualify if…
You will receive standard treatment for Hodgkin lymphoma based on your stage and risk factors, which may include chemotherapy, radiation, or newer targeted drugs. During your normal cancer treatment visits and follow-up appointments — at diagnosis, after 2 cycles of chemotherapy, at the end of treatment, and then every 3 months for several years — nurses will also draw blood samples for this research. You'll also provide a cheek swab sample once at the start. The blood draws are routine and happen alongside your regular medical care; you're not receiving any new experimental medication, just allowing researchers to study your blood to see if ctDNA can predict your outcomes.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Czechia
Sponsor
Interni hematologicka klinika FNKV
Collaborators
Charles University, Czech Republic, General University Hospital, Prague
Enrollment target
~500 participants
Started
January 2022
Primary completion
December 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Heidi Mocikova, M.D., Ph.D.
Faculty Hospital Kralovske Vinohrady
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.